Skip to main content
SpringerLink
Log in

Maligne Ovarialtumoren

  • Living reference work entry
  • First Online:
DGIM Innere Medizin

Part of the book series: Springer Reference Medizin ((SRM))

  • 309 Accesses

Zusammenfassung

Das Ovarialkarzinom ist eine Erkrankung, die aufgrund ihres lange asymptomatischen Verlaufs typischerweise erst im fortgeschrittenen Stadium erkannt wird. Die Letalität ist daher weiterhin die höchste unter den gynäkologischen Malignomen. Die Therapie umfasst das operative Staging mit Entfernung des makroskopisch sichtbaren Tumors und die platintaxanhaltige Chemotherapie in adjuvanter oder neoadjuvanter Form. Aufgrund des herausragenden Stellenwerts der kompletten operativen Tumorentfernung für die Prognose der Patientin erfordert die Operation ein erfahrenes, interdiziplinär arbeitendes, gynäkologisch-onkologisches Team und eine Krankenhausstruktur, in der auch eine Patientin mit erhöhter perioperativer Morbidität behandelt werden kann. Die Prognose der Patientin ist daher abhängig von den Behandlungsfällen pro Operateur und Krankenhaus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039–2045

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950–1955

    Article  CAS  PubMed  Google Scholar 

  • Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43

    Article  CAS  PubMed  Google Scholar 

  • Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42(5):589–597

    Article  PubMed  Google Scholar 

  • Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK (2009) Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol 115(3):334–338

    Article  PubMed  Google Scholar 

  • Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473–2483

    Article  CAS  PubMed  Google Scholar 

  • Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR et al (2006a) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9):1933–1939

    Article  PubMed  Google Scholar 

  • Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006b) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103(2):559–564

    Article  CAS  PubMed  Google Scholar 

  • Debald M, Kaiser C, Abramian A, Schildhaus HU, Locher P, Wolfgarten M, Kuhn W, Braun M (2013) Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer. Anticancer Res 33(5):1971–1975

    CAS  PubMed  Google Scholar 

  • Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11

    CAS  PubMed  Google Scholar 

  • du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T et al (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer 49(8):1905–1914

    Article  PubMed  Google Scholar 

  • Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR et al (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103(3):1083–1090

    Article  PubMed  Google Scholar 

  • Gough IR, Balderson GA (1993) Malignant ascites. A comparison of peritoneovenous shunting and nonoperative management. Cancer 71(7):2377–2382

    Article  CAS  PubMed  Google Scholar 

  • Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schroder W et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710

    Article  PubMed  Google Scholar 

  • Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A et al (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16(5):1324–1330

    Article  CAS  PubMed  Google Scholar 

  • Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U (2006) Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(suppl 1):161–192

    Article  Google Scholar 

  • Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127(9):2209–2221

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Helm CW (2012a) Ports and complications for intraperitoneal chemotherapy delivery. BJOG 119(2):150–159

    Article  CAS  PubMed  Google Scholar 

  • Helm CW (2012b) Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am 21(4):645–663

    Article  PubMed  Google Scholar 

  • Keyver-Paik MD, Zivanovic O, Rudlowski C, Holler T, Wolfgarten M, Kubler K, Schroder L, Mallmann MR, Polcher M, Kuhn W (2013) Interval debulking surgery in patients with Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV ovarian cancer. Onkologie 36(6):324–332

    Article  PubMed  Google Scholar 

  • Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92(10):2585–2591

    Article  CAS  PubMed  Google Scholar 

  • Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433–443

    Article  PubMed Central  PubMed  Google Scholar 

  • Lee CW, Bociek G, Faught W (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manage 16(2):96–101

    Article  CAS  PubMed  Google Scholar 

  • Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19(4):1001–1007

    CAS  PubMed  Google Scholar 

  • Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J et al (2010) Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28(19):3107–3114

    Article  CAS  PubMed  Google Scholar 

  • Narod SA, Moody JR, Rosen B, Fan I, Risch A, Sun P, McLaughlin JR (2013) Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clin Genet 83(3):232–237

    Article  CAS  PubMed  Google Scholar 

  • Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375):2099–2106

    Article  CAS  PubMed  Google Scholar 

  • Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496

    Article  CAS  PubMed  Google Scholar 

  • Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart G, Kimmig R et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24(29):4699–4707

    Article  CAS  PubMed  Google Scholar 

  • Robert-Koch-Institut GdeKeVGudZfKZi: Krebs in Deutschland. 2012

    Google Scholar 

  • Rochet N, Sterzing F, Jensen AD, Dinkel J, Herfarth KK, Schubert K, Eichbaum MH, Schneeweiss A, Sohn C, Debus J et al (2010) Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys 76(5):1382–1389

    Article  CAS  PubMed  Google Scholar 

  • Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376(9747):1155–1163

    Article  PubMed  Google Scholar 

  • Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M et al (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 273(7):535–541

    Article  CAS  PubMed  Google Scholar 

  • Siewert J (Hrsg) (2010) Onkologische Chirurgie. In: Pölcher M, Schmalfeldt G, Florack J, Kalff J, Kuhn W Ovarialkarzinom. Springer Medizin Verlag, Heidelberg

    Google Scholar 

  • Sobin LH, Gospodarowicz MK, Wittekind C (Hrsg) (2009) UICC: TNM classification of malignant tumors, 7. Aufl. Wiley-Blackwell

    Google Scholar 

  • Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS et al (2012) The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 10(5):296–306

    PubMed  Google Scholar 

  • Jr. van Nagell JR, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ (2007) Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109(9):1887–1896

    Article  PubMed  Google Scholar 

  • Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953

    Article  CAS  PubMed  Google Scholar 

  • Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107(4):588–591

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • White MA, Agle SC, Padia RK, Zervos EE (2011) Denver peritoneovenous shunts for the management of malignant ascites: a review of the literature in the post LeVeen Era. Am Surg 77(8):1070–1075

    PubMed  Google Scholar 

  • Zivanovic O AA, Keyver-Paik M-D, Poelcher M, Rudlowski C, Kuhn W (2013) HIPEC ROC I Study of Cisplatin administered as Hyperthermic Intraoperative Intraperitoneal Chemoperfusion followed by Postoperative Intravenous Platinum-based Chemotherapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer. submitted to Lancet Oncology 2013

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland

    Mignon-Denise Keyver-Paik & Walther Kuhn

  2. Klinik I für Innere Medizin, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland

    Kai Hübel

Authors
  1. Mignon-Denise Keyver-Paik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walther Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kai Hübel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mignon-Denise Keyver-Paik .

Editor information

Editors and Affiliations

  1. Medizinische Klinik I, Universitätsklinikum Schleswig-Hoslstein, Campus Lübeck, Lübeck, Schleswig-Holstein, Germany

    Hendrik Lehnert

  2. TU Dresden Universitätsklinikum Carl Gustav Carus, Dresden, Germany

    Sebastian M. Schellong

  3. FB Gastroenterologie und Hepatologie, Universitätsklinikum Leipzig Medizinische Klinik und Poliklinik II, Leipzig, Sachsen, Germany

    Joachim Mössner

  4. Krankenhaus Barmherzige Brüder, Regensburg, Germany

    Cornel C. Sieber

  5. Nürnberg, Bayern, Germany

    Walter Swoboda

  6. Universitätsklinikum Giessen und Marburg Klinik für Innere Medizin, Marburg, Hessen, Germany

    Andreas Neubauer

  7. Interdisziplinärer Schwerpunkt für Hämos, Universitätsklinikum Gießen und Marburg, Gießen, Germany

    Bettina Kemkes-Matthes

  8. Klinik für Gastroenterologie,Hepatologie, Medizinische Hochschule Hannover, Hannover, Germany

    Michael P. Manns

  9. Sektion für Molekulare und Klinische Inf, Universitätsklinikum Schleswig-Holstein,, Lübeck, Germany

    Jan Rupp

  10. Abt. Kardiologie und Pneumologie, Universitätsklinikum Göttingen Herzzentrum Göttingen, Göttingen, Germany

    Gerd Hasenfuß

  11. Abt. Nephrologie und Klinische Immunologie, Univ.Klinikum Aachen Medizinische Klinik II, Aachen, Germany

    J. Floege

  12. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Michael Hallek

  13. Klinik für Pneumologie, Medizinische Hochschule Hannover (MHH) Zentrum Innere Medizin, Hannover, Germany

    Tobias Welte

  14. Klinik u. Poliklinik für Innere Medizin, Universitätsmedizin Greifswald, Greifswald, Germany

    Markus Lerch

  15. Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany

    Elisabeth Märker-Hermann

  16. Klinische Toxikologie, Giftinformation, Universitätsklinikum Mainz II. Medizinische Klinik und Poliklinik, Mainz, Germany

    Ludwig Sacha Weilemann

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Keyver-Paik, MD., Kuhn, W., Hübel, K. (2015). Maligne Ovarialtumoren. In: Lehnert, H., et al. DGIM Innere Medizin. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54676-1_503-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54676-1_503-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-54676-1

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation